← Back to patent-cliff list

CAS 1193-24-4

4,6-Dihydroxypyrimidinepyrimidine-4,6-diol

Codes: (I)461018-10-a, ITACI-029

Application context (from source-drug indications)

Waldenström macroglobulinaemiaIbrutinibChronic lymphocytic leukaemiaIbrutinibMantle cell lymphomaIbrutinibGraft-versus-host diseaseIbrutinibDiffuse large B-cell lymphomaItacitinibMyeloproliferative neoplasmItacitinibAcute lymphoblastic leukaemiaItacitinibAcute myeloid leukaemiaItacitinibChronic myelomonocytic leukaemiaItacitinib骨髓增生异常-骨髓增生性疾病Itacitinib

Source drugs (routes using this intermediate)

DrugTierExpiry
IbrutinibTier A — Act now2027
ItacitinibTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.